Safety comes first – in all areas

Due to the worsening COVID 19 pandemic, STORZ MEDICAL has taken a number of measures to protect our employees, customers and partners in the best possible way and to ensure business operations. We are guided by the recommendations of international and national authorities.

In February 2020, STORZ MEDICAL has received the CE approval for the MAGNETOLITH® system, which is the successor of the CELLACTOR® MT1. Extracorporeal Magnetotransduction Therapy (EMTT®) with the MAGNETOLITH® opens up new possibilities in regeneration and rehabilitation. The areas of application include diseases of the musculoskeletal system such as lower back pain and tendinopathies of the rotator cuff or Achilles tendon. The non-invasive, outpatient therapy is virtually free of side effects.

40 years ago, on 7 February 1980, the first treatment of a kidney stone patient with shock waves was performed at the Department of Urology of Munich University Hospital based at the Grosshardern campus. Several STORZ MEDICAL employees from the company’s research, development and marketing departments were present to witness the historic event, which ushered in a new era in medical technology: the era of extracorporeal shock wave lithotripsy (ESWL).

For years, STORZ MEDICAL has been teaming up with medical specialists to pioneer the development of radial shock wave transmitters, which are used to treat myofascial conditions. One of the challenges that medical professionals face every day when using shock waves is ensuring that treatment of particularly sensitive and deep-lying trigger points and myofascial imbalances is gentle, effective and virtually pain-free.

In 2018, Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system was the first, and hitherto only, procedure of its kind to obtain market authorization for the »treatment of the central nervous system of patients with Alzheimer’s disease«. TPS was developed by STORZ MEDICAL in collaboration with a team of researchers from the Medical University of Vienna (Department of Neurology), led by Professor Roland Beisteiner, and Dr. Henning Lohse-Busch, Rheintalklinik, Bad Krozingen. In December 2019, the prestigious journal »Advanced Science« published a study, in which Beisteiner et al. evaluate the method and present first treatment results. The presented data shows that it is possible to improve brain performance with TPS and that there is a long-term effect.